colchicine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
726 64-86-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • colchicine
  • colchisol
  • colcin
A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (PERIODIC DISEASE).
  • Molecular weight: 399.44
  • Formula: C22H25NO6
  • CLOGP: 1.20
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 83.09
  • ALOGS: -4.16
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 mg O
1 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.29 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
S (Water solubility) 45 mg/mL Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 6.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.61 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 58 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 27, 1961 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 478.73 37.49 140 821 32614 2324510
Diarrhoea 430.05 37.49 162 799 83402 2273722
Pancytopenia 200.91 37.49 57 904 11395 2345729
Drug interaction 193.13 37.49 69 892 29094 2328030
Vomiting 178.71 37.49 84 877 71518 2285606
Acute kidney injury 169.04 37.49 62 899 28060 2329064
Drug reaction with eosinophilia and systemic symptoms 160.45 37.49 41 920 5477 2351647
Multiple organ dysfunction syndrome 138.07 37.49 39 922 7602 2349522
Off label use 134.48 37.49 70 891 73528 2283596
Intentional overdose 131.30 37.49 41 920 11280 2345844
Drug ineffective 129.08 37.49 76 885 101548 2255576
Nausea 117.02 37.49 74 887 112115 2245009
Exposure during pregnancy 116.55 37.49 46 915 25173 2331951
Leukopenia 110.13 37.49 35 926 10161 2346963
Gout 107.07 37.49 23 938 1432 2355692
Treatment failure 104.24 37.49 31 930 7208 2349916
Disseminated intravascular coagulation 97.73 37.49 25 936 3325 2353799
Completed suicide 95.77 37.49 38 923 20996 2336128
Drug hypersensitivity 95.28 37.49 48 913 46595 2310529
Abdominal pain 93.25 37.49 43 918 34331 2322793
Drug intolerance 92.29 37.49 33 928 13684 2343440
Rhabdomyolysis 89.10 37.49 27 934 6677 2350447
Suicide attempt 82.93 37.49 29 932 11253 2345871
Product use in unapproved indication 71.72 37.49 26 935 11174 2345950
Enterococcal sepsis 67.63 37.49 11 950 144 2356980
Septic shock 67.00 37.49 22 939 7032 2350092
Metabolic acidosis 66.33 37.49 21 940 5977 2351147
International normalised ratio increased 66.16 37.49 22 939 7314 2349810
Anaphylactic reaction 63.87 37.49 23 938 9682 2347442
Overdose 63.66 37.49 28 933 19879 2337245
Bone marrow failure 63.26 37.49 20 941 5666 2351458
Myopathy 62.50 37.49 15 946 1528 2355596
Product use issue 62.36 37.49 24 937 12145 2344979
Appetite disorder 57.89 37.49 12 949 625 2356499
Blood creatine phosphokinase increased 52.73 37.49 17 944 5119 2352005
Sjogren's syndrome 52.25 37.49 12 949 1009 2356115
Pyrexia 51.87 37.49 34 927 53674 2303450
Rash maculo-papular 51.64 37.49 16 945 4236 2352888
Hepatic failure 51.02 37.49 17 944 5672 2351452
Abdominal discomfort 50.80 37.49 23 938 17433 2339691
Leukocytosis 50.01 37.49 15 946 3561 2353563
Thrombocytopenia 48.78 37.49 23 938 19108 2338016
Alopecia 48.69 37.49 24 937 21977 2335147
Dehydration 48.39 37.49 24 937 22271 2334853
Hypertriglyceridaemia 48.37 37.49 11 950 885 2356239
Cardiac arrest 47.68 37.49 21 940 14909 2342215
Behcet's syndrome 45.89 37.49 8 953 162 2356962
Rheumatoid arthritis 45.71 37.49 22 939 19118 2338006
Erythema 45.65 37.49 24 937 25135 2331989
Skin disorder 45.50 37.49 14 947 3617 2353507
Musculoskeletal stiffness 44.91 37.49 19 942 12228 2344896
Pulmonary mass 44.68 37.49 12 949 1914 2355210
Rash 44.03 37.49 32 929 59526 2297598
Disease recurrence 41.95 37.49 13 948 3438 2353686
Cardiogenic shock 41.63 37.49 12 949 2479 2354645
Arthritis infective 40.66 37.49 9 952 640 2356484
Weight decreased 40.22 37.49 23 938 28348 2328776
Tenderness 40.05 37.49 11 950 1907 2355217
Neuromyopathy 38.97 37.49 7 954 169 2356955
Asthenia 38.76 37.49 27 934 46899 2310225
Dyspnoea 38.17 37.49 33 928 78700 2278424

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 647.32 43.90 199 920 28942 1716720
Diarrhoea 531.04 43.90 200 919 53652 1692010
Completed suicide 368.78 43.90 114 1005 16198 1729464
Acute kidney injury 308.55 43.90 121 998 34823 1710839
Gout 274.16 43.90 62 1057 2554 1743108
Drug interaction 257.21 43.90 100 1019 27858 1717804
Rhabdomyolysis 247.28 43.90 77 1042 11013 1734649
Overdose 208.70 43.90 75 1044 16626 1729036
Vomiting 169.68 43.90 82 1037 38233 1707429
Multiple organ dysfunction syndrome 167.74 43.90 55 1064 9187 1736475
Pancytopenia 137.61 43.90 50 1069 11307 1734355
Myopathy 131.68 43.90 32 1087 1781 1743881
Hypotension 123.39 43.90 61 1058 29593 1716069
Intentional overdose 120.47 43.90 41 1078 7629 1738033
Thrombocytopenia 110.45 43.90 51 1068 21198 1724464
Renal failure 110.17 43.90 50 1069 19967 1725695
Cardiac arrest 97.82 43.90 43 1076 15887 1729775
Neuromyopathy 91.16 43.90 16 1103 168 1745494
Abdominal pain 88.50 43.90 44 1075 21446 1724216
Alanine aminotransferase increased 84.66 43.90 36 1083 12242 1733420
Metabolic acidosis 81.27 43.90 28 1091 5374 1740288
Hepatitis 75.75 43.90 26 1093 4929 1740733
Drug reaction with eosinophilia and systemic symptoms 75.17 43.90 26 1093 5044 1740618
Blood creatine phosphokinase increased 67.79 43.90 28 1091 8828 1736834
Hepatotoxicity 66.51 43.90 21 1098 3063 1742599
Nausea 66.45 43.90 50 1069 51146 1694516
Neutropenia 65.19 43.90 34 1085 18226 1727436
Leukocytosis 63.71 43.90 21 1098 3512 1742150
Poisoning deliberate 61.75 43.90 15 1104 827 1744835
Blood creatinine increased 61.57 43.90 30 1089 13916 1731746
Dehydration 60.51 43.90 32 1087 17626 1728036
Drug ineffective 58.79 43.90 51 1068 63750 1681912
Suicide attempt 58.71 43.90 24 1095 7357 1738305
Myalgia 58.28 43.90 30 1089 15628 1730034
Cardiogenic shock 54.10 43.90 17 1102 2437 1743225
Aspartate aminotransferase increased 53.10 43.90 25 1094 10731 1734931
Shock 52.71 43.90 19 1100 4142 1741520
Off label use 50.63 43.90 38 1081 38533 1707129
Chondrocalcinosis 50.43 43.90 8 1111 42 1745620
Blood uric acid increased 49.32 43.90 13 1106 996 1744666
Drug intolerance 49.18 43.90 20 1099 6042 1739620
Acute respiratory distress syndrome 47.94 43.90 17 1102 3534 1742128
Blood urea increased 46.81 43.90 18 1101 4693 1740969
Gastrointestinal disorder 46.67 43.90 18 1101 4730 1740932
Hyperkalaemia 45.69 43.90 21 1098 8526 1737136
Pyrexia 44.43 43.90 38 1081 46362 1699300

Pharmacologic Action:

SourceCodeDescription
ATC M04AC01 MUSCULO-SKELETAL SYSTEM
ANTIGOUT PREPARATIONS
ANTIGOUT PREPARATIONS
Preparations with no effect on uric acid metabolism
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000000239 P-Glycoprotein Interactions
MeSH PA D050256 Antimitotic Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D006074 Gout Suppressants
MeSH PA D050257 Tubulin Modulators

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Familial Mediterranean fever indication 12579009 DOID:2987
Chronic gouty arthritis indication 68451005
Gout indication 90560007 DOID:13189
Gout Prevention indication
Peptic ulcer contraindication 13200003 DOID:750
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Diarrhea contraindication 62315008
Leukopenia contraindication 84828003 DOID:615
Anemia due to enzyme deficiency contraindication 111577008
Disorder of muscle contraindication 129565002 DOID:423
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Impaired renal function disorder contraindication 197663003
Rhabdomyolysis contraindication 240131006
Renal dialysis contraindication 265764009
Uric acid renal calculus contraindication 274401005
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Aplastic anemia contraindication 306058006 DOID:12449
Bone marrow depression contraindication 307762000
Granulocytopenic disorder contraindication 417672002
Vomiting contraindication 422400008
Uric Acid Nephropathy Gout contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.19 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7964647 Oct. 6, 2028 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7964648 Oct. 6, 2028 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7981938 Oct. 6, 2028 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8093296 Oct. 6, 2028 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8093297 Oct. 6, 2028 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8093298 Oct. 6, 2028 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8097655 Oct. 6, 2028 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8415395 Oct. 6, 2028 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8415396 Oct. 6, 2028 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7619004 Dec. 3, 2028 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7935731 Dec. 3, 2028 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7601758 Feb. 10, 2029 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7820681 Feb. 17, 2029 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7906519 Feb. 17, 2029 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7915269 Feb. 17, 2029 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8440721 Feb. 17, 2029 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8440722 Feb. 17, 2029 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG MITIGARE HIKMA INTL PHARMS N204820 Sept. 26, 2014 RX CAPSULE ORAL 8927607 Aug. 22, 2033 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG MITIGARE HIKMA INTL PHARMS N204820 Sept. 26, 2014 RX CAPSULE ORAL 9399036 Aug. 22, 2033 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG MITIGARE HIKMA INTL PHARMS N204820 Sept. 26, 2014 RX CAPSULE ORAL 9555029 Aug. 22, 2033 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG MITIGARE HIKMA INTL PHARMS N204820 Sept. 26, 2014 RX CAPSULE ORAL 9675613 Aug. 22, 2033 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG MITIGARE HIKMA INTL PHARMS N204820 Sept. 26, 2014 RX CAPSULE ORAL 9789108 Aug. 22, 2033 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
Glycine receptor subunit alpha-2 Ion channel IC50 4.19 WOMBAT-PK
Tubulin beta-4B chain Structural Ki 5.24 WOMBAT-PK
Glycine receptor subunit alpha-1 Ion channel IC50 3.49 WOMBAT-PK
Multidrug resistance protein 1 Transporter Kd 3.80 WOMBAT-PK
Cytochrome P450 3A4 Enzyme Ki 4.19 WOMBAT-PK
Tubulin beta chain Structural INHIBITOR Ki 5.24 WOMBAT-PK
Tubulin Structural Ki 5.24 CHEMBL
Tubulin alpha-1A chain Structural Ki 5.60 CHEMBL
Tubulin beta-2B chain Structural Ki 6.11 CHEMBL
Tubulin Structural IC50 6.10 CHEMBL
Tubulin polymerization-promoting protein Unclassified EC50 6.12 CHEMBL

External reference:

IDSource
D003078 MESH_DESCRIPTOR_UI
4020930 VUID
N0000148412 NUI
C0009262 UMLSCUI
D00570 KEGG_DRUG
73133000 SNOMEDCT_US
4020930 VANDF
4017416 VANDF
002372 NDDF
581 MMSL
2683 RXNORM
387413002 SNOMEDCT_US
4493 MMSL
d00150 MMSL
CHEMBL107 ChEMBL_ID
SML2Y3J35T UNII
LOC PDB_CHEM_ID
DB01394 DRUGBANK_ID
CHEBI:27882 CHEBI
2367 IUPHAR_LIGAND_ID
6167 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0143-3018 CAPSULE 0.60 mg ORAL NDA 18 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0254-2008 TABLET, FILM COATED 0.60 mg ORAL NDA AUTHORIZED GENERIC 18 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0378-1086 TABLET, FILM COATED 0.60 mg ORAL ANDA 18 sections
Probenecid and Colchicine HUMAN PRESCRIPTION DRUG LABEL 2 0591-5325 TABLET 0.50 mg ORAL ANDA 10 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6732 CAPSULE 0.60 mg ORAL NDA 18 sections
Colcrys HUMAN PRESCRIPTION DRUG LABEL 1 13310-119 TABLET, FILM COATED 0.60 mg ORAL NDA 18 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 42292-054 TABLET, FILM COATED 0.60 mg ORAL ANDA 18 sections
Colcrys HUMAN PRESCRIPTION DRUG LABEL 1 43353-854 TABLET, FILM COATED 0.60 mg ORAL NDA 19 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3465 CAPSULE 0.60 mg ORAL NDA 18 sections
Probenecid and Colchicine HUMAN PRESCRIPTION DRUG LABEL 2 50742-263 TABLET 0.50 mg ORAL ANDA 10 sections
Colcrys HUMAN PRESCRIPTION DRUG LABEL 1 54868-6256 TABLET, FILM COATED 0.60 mg ORAL NDA 18 sections
MITIGARE HUMAN PRESCRIPTION DRUG LABEL 1 59467-318 CAPSULE 0.60 mg ORAL NDA 18 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 60687-358 CAPSULE 0.60 mg ORAL NDA 18 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 60687-389 TABLET, FILM COATED 0.60 mg ORAL NDA authorized generic 19 sections
Colcrys HUMAN PRESCRIPTION DRUG LABEL 1 63187-292 TABLET, FILM COATED 0.60 mg ORAL NDA 19 sections
Colcrys HUMAN PRESCRIPTION DRUG LABEL 1 64764-119 TABLET, FILM COATED 0.60 mg ORAL NDA 18 sections
Probenecid and Colchicine HUMAN PRESCRIPTION DRUG LABEL 2 64980-149 TABLET 0.50 mg ORAL ANDA 10 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 65162-710 TABLET 0.60 mg ORAL ANDA 18 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 66993-165 TABLET, FILM COATED 0.60 mg ORAL NDA authorized generic 18 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 67296-1708 TABLET, FILM COATED 0.60 mg ORAL NDA authorized generic 18 sections
colchicine HUMAN PRESCRIPTION DRUG LABEL 1 67877-589 TABLET 0.60 mg ORAL ANDA 18 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 70010-002 TABLET, FILM COATED 0.60 mg ORAL ANDA 17 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 71205-310 TABLET, FILM COATED 0.60 mg ORAL NDA authorized generic 18 sections
Gloperba HUMAN PRESCRIPTION DRUG LABEL 1 72690-010 SOLUTION 0.60 mg ORAL NDA 17 sections
Gloperba HUMAN PRESCRIPTION DRUG LABEL 1 75854-801 SOLUTION 0.60 mg ORAL NDA 17 sections